Sichuan Province Shuzhong Pharmacy Co., Ltd.

Celecoxib capsules (specification: 0.2g) produced by Sichuan Yike Pharmaceutical Co., Ltd. were used as the test preparation, and celecoxib capsules (trade name: Celebrex®, specification: 0.2g) produced by Pfizer Pharmaceuticals LLC were used as the reference preparation. According to the relevant regulations of bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated.

Main purpose: Diclofenac sodium sustained-release tablets (specification: 0.1g) of Sichuan Yike Pharmaceutical Co., Ltd. were used as the test preparation, and diclofenac sodium sustained-release tablets (trade name: VOLTAREN®, specification: 100mg) certified by Novartis Pharma GmbH were used as the reference preparation. According to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: This study uses the empagliflozin tablets (specification: 25 mg) certified by Sichuan Yike Pharmaceutical Co., Ltd. as the test preparation and the empagliflozin tablets (trade name: Jardiance®, specification: 25 mg) certified by Boehringer Ingelheim International GmbH as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.